Phosphodiesterase

Global PDE Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 2, 2021
Health, Clinical Trials, News, COPD, Discovery, Psoriasis, Chronic obstructive pulmonary disease, Technology, Inflammation, Acquisition, PDE4, Route, Phosphodiesterase, Dermatology, Clinical trial, Route of administration, Therapy, ROA, PDE3, Atopic dermatitis, Chronic, Administration, NDA, FDA, Enzyme, Dermatitis, Pharmaceutical industry

This report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in PDE Inhibitors pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in PDE Inhibitors pipeline landscape.
  • A detailed picture of the PDE Inhibitors pipeline landscape is provided which includes the disease overview and PDE Inhibitors treatment guidelines.
  • The assessment part of the report embraces, in depth PDE Inhibitors commercial assessment and clinical assessment of the pipeline products under development.
  • PDE Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA®

Retrieved on: 
Tuesday, July 27, 2021
Chemical compounds, PDE5 inhibitors, Organic compounds, Chemistry, cGMP-specific phosphodiesterase type 5, Avanafil, Phosphodiesterase, Erectile dysfunction, Sildenafil, Phosphodiesterase inhibitor

"While the PDE5 inhibitor class of erectile dysfunction drugs has a respected history, we believe that the data collected on STENDRA may further differentiate it from other drugs in the class.

Key Points: 
  • "While the PDE5 inhibitor class of erectile dysfunction drugs has a respected history, we believe that the data collected on STENDRA may further differentiate it from other drugs in the class.
  • We look forward to sharing our data with the FDA and discussing the additional necessary steps toward modification of the STENDRA label, and thereby the patient populations that may benefit from treating their erectile dysfunction with STENDRA."
  • Stendra(avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.
  • STENDRA may affect the way other medicines work, and other medicines may affect the way STENDRA works, which may cause side effects.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Pharmaceutical, Health, Clinical trials, Molecular biology, Phosphodiesterase, Phosphodiester bond, PDE1, PDE4B, Benjamin Weiss

The "Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 cyclic nucleotide phosphodiesterase inhibitors pipeline landscape.
  • Type 4 cyclic nucleotide phosphodiesterase inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Type 4 cyclic nucleotide phosphodiesterase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Type 4 cyclic nucleotide phosphodiesterase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds

Retrieved on: 
Tuesday, February 23, 2021
Chemistry, Branches of biology, Chemical compounds, Molecular biology, cGMP-specific phosphodiesterase type 5, Phosphodiesterase, Travoprost, Phosphodiester bond, Nitric oxide, NicOx

The NO-mediated IOP-lowering effect in this new class of compounds is enhanced by concomitant action of phosphodiesterase type-5 (PDE5) inhibition within the same molecule.

Key Points: 
  • The NO-mediated IOP-lowering effect in this new class of compounds is enhanced by concomitant action of phosphodiesterase type-5 (PDE5) inhibition within the same molecule.
  • This new class of compounds enhance the nitric oxide-mediated intraocular pressure lowering effect with the concomitant action of phosphodiesterase type-5 inhibition.
  • Travoprost is a prostaglandin analog, a class of molecules which are considered standard of care for IOP lowering in humans.
  • NCX 1728 is the first in this new class of compounds to be selected for development (See Press Release of October 23, 2020 ).

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

Retrieved on: 
Monday, February 1, 2021
Phosphodiesterase-4 inhibitor, Psoriasis, Phosphodiesterase 4, Phosphodiesterase, Organ systems, Medical specialties

(Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream ( ARQ-151 ) as a potential topical treatment for plaque psoriasis .

Key Points: 
  • (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream ( ARQ-151 ) as a potential topical treatment for plaque psoriasis .
  • Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4).
  • Overall, 90% of patients who were randomized to roflumilast cream in the studies completed the full 8 weeks.
  • Roflumilast Cream is a topical cream formulation of a highly potent and selective PDE4 inhibitor (roflumilast).

Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

Retrieved on: 
Wednesday, January 20, 2021
Chemical compounds, Benzamides, Aromatic compounds, Seborrhoeic dermatitis, Roflumilast, Dermatitis, Phosphodiesterase 4, Phosphodiesterase, Phosphodiesterase-4 inhibitor

Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor.

Key Points: 
  • Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor.
  • Following our interactions with the FDA, we are delighted to advance topical roflumilast foam into Phase 3 development for the treatment of seborrheic dermatitis, a disease that affects more than 10 million people in the U.S., said Patrick Burnett, M.D., Ph.D., FAAD, Arcutis Chief Medical Officer .
  • If successful in the Phase 3 clinical trial and approved for commercialization, roflumilast foam has the potential to become the standard of care in seborrheic dermatitis.
  • Arcutis believes roflumilast foam has significant potential as a treatment for seborrheic dermatitis.

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Retrieved on: 
Tuesday, October 13, 2020
Drugs, Clinical medicine, Health, Chronic lower respiratory diseases, Combination drugs, Muscarinic antagonists, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, RPL-554, Phosphodiesterase, Fluticasone furoate/umeclidinium bromide/vilanterol, Fluticasone furoate/vilanterol

U.S. sales of medicines used for chronic maintenance therapy of COPD were $9.6 billion in 2019.

Key Points: 
  • U.S. sales of medicines used for chronic maintenance therapy of COPD were $9.6 billion in 2019.
  • About 1.2 million U.S. COPD patients on dual/triple inhaled therapy, long-acting beta-agonist (LABA)/long-acting muscarinic antagonist (LAMA) +/- inhaled corticosteroid (ICS) remain uncontrolled, experiencing symptoms that impair quality of life.
  • Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4).
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.

The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

Retrieved on: 
Wednesday, July 15, 2020
Chemical compounds, Organ systems, Phosphodiesterase-4 inhibitor, Psoriasis, Benzamides, Roflumilast, Phosphodiesterase, Phosphodiesterase inhibitor

Roflumilast cream (ARQ-151) is a once-daily, highly potent, selective phosphodiesterase-4 (PDE-4) inhibitor being developed for chronic plaque psoriasis.

Key Points: 
  • Roflumilast cream (ARQ-151) is a once-daily, highly potent, selective phosphodiesterase-4 (PDE-4) inhibitor being developed for chronic plaque psoriasis.
  • Arcutis is currently conducting a Phase 3 clinical program with topical roflumilast cream, including two ongoing Phase 3 clinical trials (DERMIS-1 and -2).
  • Please refer to the paper, Trial of Roflumilast Cream for Chronic Plaque Psoriasis for the full description of the design and results of this study.
  • Topical roflumilast cream is a once-daily, topical cream formulation containing roflumilast, a PDE4 inhibitor, that Arcutis is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis.

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Evolving Opportunities with AstraZeneca and Merck | Technavio

Retrieved on: 
Friday, January 17, 2020
Biotechnology, Pharmaceutical, Health, Phosphodiesterase inhibitors, Branches of biology, Molecular biology, Phosphodiesterase, PD-1 and PD-L1 inhibitors, PD-L1, Biology

View the full release here: https://www.businesswire.com/news/home/20200117005292/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200117005292/en/
    Technavio has announced its latest market research report titled global PD-1 and PD-L1 inhibitors market 2019-2023.
  • The proven efficiency of PD-1 and PD-L1 inhibitors and strong pipeline are among factors anticipated to boost the growth of the market.
  • Request a free sample report
    Related Reports on Health Care include:
    MEK Inhibitors Market Global MEK Inhibitors Market by product (MEKINIST, COTELLIC, and MEKTOVI) and geography (Asia, Europe, North America, and ROW).
  • Phosphodiesterase (PDE) inhibitors Market Global Phosphodiesterase (PDE) inhibitors Market by application (oral, topical, and other RoA), and geography (Asia, Europe, North America, and ROW).

Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Health, Pharmaceutical, Enzymes, Autotaxin, Phosphodiesterase, Nucleotide pyrophosphatase/phosphodiesterase, Alkylglycerophosphoethanolamine phosphodiesterase, Phospholipase, ENPP3, Ectonucleotide pyrophosphatase/phosphodiesterase 1

The "Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene.
  • Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 17 molecules.
  • The latest report Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.